Maurizio Ceppi PhD

Genetics
Illkirch-graffenstaden, Grand Est, France

Connect with the speaker?

Maurizio Ceppi is a biotech executive with over 15 years of experience in oncology drug development and diagnostics, specializing in translational medicine. With deep expertise in cancer immunotherapy, he has contributed to the development of monoclonal and bispecific antibodies, small molecules, and mRNA vaccines. Maurizio is currently serving as Chief Scientific Officer (CSO) at Transgene, a Biotech company at the forefront of developing individualized cancer vaccines, leveraging artificial intelligence (AI) to design tailored immunotherapies that target specific tumor mutations called neoantigens, thereby enhancing the body's immune response to cancer.
Previously, at Roche, Maurizio was responsible for developing the biomarker strategy for several pre-clinical and early-stage (Ph 1 / Ph 2) clinical studies for cancer immunotherapy (4-1BB) and targeted cancer therapy (HER3, BRAF inhibitor) drug candidates. As a Biomarker Leader, he led global cross-functional teams dedicated to biomarker discovery, assay development, and implementation in clinical settings, including CDx feasibility assessment. Notably, he participated in regulatory interactions with the FDA, contributing to the successful transition of four molecules to IND submission.

EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)

Keep up with our latest news and events.Subscribe to our newsletter